BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 30157869)

  • 1. NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson's disease.
    Cheng L; Chen L; Wei X; Wang Y; Ren Z; Zeng S; Zhang X; Wen H; Gao C; Liu H
    J Neuroinflammation; 2018 Aug; 15(1):243. PubMed ID: 30157869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microglial cells are involved in the susceptibility of NADPH oxidase knockout mice to 6-hydroxy-dopamine-induced neurodegeneration.
    Hernandes MS; Santos GD; Café-Mendes CC; Lima LS; Scavone C; Munhoz CD; Britto LR
    PLoS One; 2013; 8(9):e75532. PubMed ID: 24086556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOD2 is involved in the inflammatory response after cerebral ischemia-reperfusion injury and triggers NADPH oxidase 2-derived reactive oxygen species.
    Liu H; Wei X; Kong L; Liu X; Cheng L; Yan S; Zhang X; Chen L
    Int J Biol Sci; 2015; 11(5):525-35. PubMed ID: 25892960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
    Sharma N; Nehru B
    Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice.
    Hernandes MS; Café-Mendes CC; Britto LR
    Oxid Med Cell Longev; 2013; 2013():157857. PubMed ID: 24379900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons.
    Rodriguez-Pallares J; Parga JA; Muñoz A; Rey P; Guerra MJ; Labandeira-Garcia JL
    J Neurochem; 2007 Oct; 103(1):145-56. PubMed ID: 17573824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
    Zhang FL; He Y; Zheng Y; Zhang WJ; Wang Q; Jia YJ; Song HL; An HT; Zhang HB; Qian YJ; Tong YL; Dong L; Wang XM
    CNS Neurosci Ther; 2014 Dec; 20(12):1036-44. PubMed ID: 25399812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
    Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
    Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
    Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
    Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
    Antunes MS; Cattelan Souza L; Ladd FVL; Ladd AABL; Moreira AL; Bortolotto VC; Silva MRP; Araújo SM; Prigol M; Nogueira CW; Boeira SP
    Mol Neurobiol; 2020 Jul; 57(7):3027-3041. PubMed ID: 32458386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of hydroxysafflor yellow A on dopaminergic neurons against 6-hydroxydopamine, activating anti-apoptotic and anti-neuroinflammatory pathways.
    Yang X; Li Y; Chen L; Xu M; Wu J; Zhang P; Nel D; Sun B
    Pharm Biol; 2020 Dec; 58(1):686-694. PubMed ID: 32658590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats.
    Yin WL; Yin WG; Huang BS; Wu LX
    Neurosci Lett; 2017 Sep; 657():45-52. PubMed ID: 28764908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental change on dopaminergic neurons in striatum of Parkinson disease rats.
    Chen XY; Li J; Qi WQ; Shen SH
    Histol Histopathol; 2007 Oct; 22(10):1085-90. PubMed ID: 17616935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.